Amplia Therapeutics Ltd (ATX) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.178x

Based on the latest financial reports, Amplia Therapeutics Ltd (ATX) has a cash flow conversion efficiency ratio of -0.178x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-7.65 Million ≈ $-5.41 Million USD) by net assets (AU$42.93 Million ≈ $30.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Amplia Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2010–2025)

This chart illustrates how Amplia Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Amplia Therapeutics Ltd carry for a breakdown of total debt and financial obligations.

Amplia Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Amplia Therapeutics Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Akin Tekstil AS IS:ATEKS	0.001x
Archer Materials Limited F:38A	-0.028x
Greenland Mines Ltd NASDAQ:GRML	N/A
DAEMO Engineering Co. Ltd KQ:317850	0.030x
Cross Timbers Royalty Trust NYSE:CRT	1.312x
Southport Acquisition Corp NYSE:PORT	0.020x
Matsa Resources Ltd AU:MAT	0.284x
Broadwind Energy Inc NASDAQ:BWEN	0.013x

Annual Cash Flow Conversion Efficiency for Amplia Therapeutics Ltd (2010–2025)

The table below shows the annual cash flow conversion efficiency of Amplia Therapeutics Ltd from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see Amplia Therapeutics Ltd (ATX) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-03-31	AU$21.02 Million ≈ $14.88 Million	AU$-6.89 Million ≈ $-4.87 Million	-0.328x	+27.06%
2024-03-31	AU$11.42 Million ≈ $8.08 Million	AU$-5.13 Million ≈ $-3.63 Million	-0.449x	-34.42%
2023-03-31	AU$15.84 Million ≈ $11.20 Million	AU$-5.29 Million ≈ $-3.74 Million	-0.334x	-65.79%
2022-03-31	AU$21.85 Million ≈ $15.46 Million	AU$-4.40 Million ≈ $-3.11 Million	-0.201x	+28.56%
2021-03-31	AU$10.34 Million ≈ $7.32 Million	AU$-2.92 Million ≈ $-2.06 Million	-0.282x	-16.24%
2020-03-31	AU$8.61 Million ≈ $6.09 Million	AU$-2.09 Million ≈ $-1.48 Million	-0.243x	-112.92%
2019-03-31	AU$8.66 Million ≈ $6.13 Million	AU$-987.35K ≈ $-698.61K	-0.114x	+92.41%
2018-03-31	AU$2.36 Million ≈ $1.67 Million	AU$-3.55 Million ≈ $-2.51 Million	-1.501x	-61.48%
2017-03-31	AU$6.63 Million ≈ $4.69 Million	AU$-6.16 Million ≈ $-4.36 Million	-0.930x	+21.06%
2016-03-31	AU$4.00 Million ≈ $2.83 Million	AU$-4.71 Million ≈ $-3.34 Million	-1.178x	-44.06%
2015-03-31	AU$4.87 Million ≈ $3.44 Million	AU$-3.98 Million ≈ $-2.81 Million	-0.817x	-397.85%
2014-03-31	AU$9.77 Million ≈ $6.91 Million	AU$-1.60 Million ≈ $-1.14 Million	-0.164x	-5.13%
2013-03-31	AU$11.23 Million ≈ $7.95 Million	AU$-1.75 Million ≈ $-1.24 Million	-0.156x	+60.77%
2012-03-31	AU$3.19 Million ≈ $2.26 Million	AU$-1.27 Million ≈ $-899.95K	-0.398x	-50.85%
2011-03-31	AU$6.07 Million ≈ $4.30 Million	AU$-1.60 Million ≈ $-1.13 Million	-0.264x	+22.54%
2010-03-31	AU$5.98 Million ≈ $4.23 Million	AU$-2.04 Million ≈ $-1.44 Million	-0.341x	--

About Amplia Therapeutics Ltd

AU:ATX Australia Biotechnology

Market Cap

$50.82 Million

AU$71.83 Million AUD

Market Cap Rank

#21825 Global

#789 in Australia

Share Price

AU$0.14

Change (1 day)

-6.67%

52-Week Range

AU$0.05 - AU$0.36

All Time High

AU$16.20